GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UnicoCell Biomed Co Ltd (TPE:6794) » Definitions » Capex-to-Operating-Income

UnicoCell Biomed Co (TPE:6794) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is UnicoCell Biomed Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

UnicoCell Biomed Co's Capital Expenditure for the three months ended in Mar. 2025 was NT$-1.91 Mil. Its Operating Income for the three months ended in Mar. 2025 was NT$-31.16 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


UnicoCell Biomed Co Capex-to-Operating-Income Historical Data

The historical data trend for UnicoCell Biomed Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UnicoCell Biomed Co Capex-to-Operating-Income Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

UnicoCell Biomed Co Quarterly Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of UnicoCell Biomed Co's Capex-to-Operating-Income

For the Biotechnology subindustry, UnicoCell Biomed Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UnicoCell Biomed Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UnicoCell Biomed Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where UnicoCell Biomed Co's Capex-to-Operating-Income falls into.


;
;

UnicoCell Biomed Co Capex-to-Operating-Income Calculation

UnicoCell Biomed Co's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-5.705) / -102.919
=N/A

UnicoCell Biomed Co's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.907) / -31.16
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UnicoCell Biomed Co  (TPE:6794) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


UnicoCell Biomed Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of UnicoCell Biomed Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


UnicoCell Biomed Co Business Description

Traded in Other Exchanges
N/A
Address
Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd focused on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The main business of the company includes new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D.

UnicoCell Biomed Co Headlines

No Headlines